semaglutide nash phase 3 essence 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Trial Phase 3 ESSENCE trial: Semaglutide

Rapid weight loss without adequate protein and resistance training typically means losing muscle along with fat

Consequently, manipulating the effects of GLP-1 has been seen as having interesting potential as a therapeutic target in type 2 diabetes

In the NEJM Phase 2 trial, participants assigned to an initial dose of 4 mg experienced significantly more adverse events than those who started at 2 mg, even when both groups ultimately reached the same target dose

Albuquerque, A., Cappello, C., Stirrup, O

They are less likely to rely on authoritative sources of medical information and more likely to make risky medical choices based on opinions and experiences shared online